UMnyango Wezizwe Zonke

Ngomhlaka-11 Juni, iKelun-Biotech yamemezela ukuthi ithuthukise ngokuzimela umuthi wayo we-TROP2 ADC sac-TMT (佳泰莱), ngokuhlanganiswa ne-PD-L1 monoclonal antibody tagitanlimab (科泰莱), inikezwe i-Breakthrough Therapy Designation (BTD) yi-Center for Drug Evaluation (CDE) ye-National Med...Funda kabanzi»

Ngomhlaka-29 Meyi, i-National Medical Products Administration (NMPA) yavuma ukudayiswa kwe-Zanidatamab, ethunyelwe yi-BeiGene, yokwelapha iziguli ezinomdlavuza we-biliary tract (BTC) ongasakwazi ukulashwa endaweni yangakini noma osakazeke kakhulu, abake bathola ukwelashwa kwesistimu ngaphambilini futhi babonisa i-HER2 ephezulu...Funda kabanzi»

Ngomhlaka-04 Juni 2025, u-Akeso umemezele ukuthi i-National Medical Products Administration (NMPA) ivumile i-PD-1/CTLA-4 bispecific antibody yenkampani yokuqala ekilasini, i-cadonilimab, yokwelapha umdlavuza wesibeletho oqhubekayo, ophindaphindayo, noma osakazekile, kanye ne-platinu...Funda kabanzi»

Ngomhlaka-29 Meyi, i-National Medical Products Administration (NMPA) yavuma i-HER2-target antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) ukuze imakethwe. Ikhonjiswa njengokwelashwa okukodwa kokwelapha iziguli ezindala ezine-metastatic non-small non-small ...Funda kabanzi»

Ngomhlaka-21 Meyi 2025, i-InnoCare Pharma yamemezela ukuthi i-China National Medical Products Administration (NMPA) ivumile i-Minjuvi® (tafasitamab), i-antibody ye-Fc-modified cytolytic CD19 eqondisa i-monoclonal antibody eyenziwe umuntu, ihlanganiswe ne-lenalidomide, kulandele i-Minjuvi monotherapy, ye-t...Funda kabanzi»

Ngomhlaka-22 Meyi 2025, i-Allist Pharmaceuticals yamemezela ukuthi umuthi wayo omusha i-Airuikai (Glecirasib Citrate Tablets), i-KRAS-G12C inhibitor, usuvunyelwe ngokusemthethweni ukuthi uqaliswe emakethe yi-National Medical Products Administration (NMPA). Ukuvunyelwa kuvumela i-Airuikai ukuthi isetshenziswe ekwelapheni...Funda kabanzi»

Ngomhlaka-22 Meyi 2025, uKelun Bio wamemezela ukuthi isicelo sesibonakaliso esisha se-trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, eyaziwa nangokuthi i-SKB264/MK – 2870) (®) samukelwe yi-Center for Drug Evaluation (...Funda kabanzi»

Empini Ende Emelene Nomdlavuza, Izikhali Ezintsha Zokulwa Nomdlavuza Zivela Ngokuqhubekayo, Ziletha Ithemba Elisha Ezigulini Empini ende phakathi kwabantu nomdlavuza, izikhali ezintsha zokulwa nomdlavuza ziyavela ngokulandelana, ziletha ithemba elisha ezigulini. Njengesiqalo esisha esikhanyayo...Funda kabanzi»

Ngo-2021, isiguli esineminyaka engu-67 ubudala esinomdlavuza we-pancreatic senza isimangaliso sezokwelapha. Ngemva kokuhlinzwa, ukuhlinzwa kaningi ngamakhemikhali, kanye nokwehluleka kokwelashwa kwe-TIL, ukuhlolwa kwezokwelapha kwe-TCR-T cell therapy esahlanganyela kukho kwenza i-metastases yamaphaphu yancipha ngo-72% zingakapheli izinyanga eziyisithupha...Funda kabanzi»

Ngomhlaka-12 Meyi 2025, i-CARsgen imemezela idatha yokuqala yezokwelapha ye-CT0596, i-CAR-T eqondiswe ku-BCMA eyenziwe kusetshenziswa ipulatifomu ye-THANK-u Plus™. I-CT0596 okwamanje iyahlolwa ocwaningweni lwezokwelapha lokuqala lokuhlola i-myeloma ephindaphindekile/engaphenduli kahle (R/R MM) noma i-relapse/refractor...Funda kabanzi»

Ngomhlaka-9 Meyi 2025, i-Hansoh Pharmaceutical yamemezela ukuthi inkomba entsha ye-Ameile (amaphilisi e-almonertinib mesylate) ivunyelwe ukumaketha. Inkomba entsha ingeyokwelashwa kweziguli ezindala ezinomdlavuza wamaphaphu ongewona amaseli amancane (i-NSCLC) ezinamathumba ane-epidermal growth factor re...Funda kabanzi»

Ngomhlaka-1 Meyi 2025, i-Hansoh Pharmaceutical imemezela ukuthi i-B7-H4-target antibody-drug conjugate (ADC) HS-20089 yeQembu eyazithuthukisa ngokwayo ukuze ijovwe ithole imvume yokufakwa njengoMuthi Oqokiwe Wokwelapha yiNational Medical Products Administration (NMPA) yaseShayina, nge...Funda kabanzi»